2024 has kicked off on a high note for the MedTech industry, witnessing a surge of groundbreaking advancements. As we step into April, it’s a fitting time to reflect on the pivotal moments encompassing funding, innovations, clinical trials, and regulatory approvals in our quarterly editors’ recap.
Funding
Biobot Surgical has recently concluded a successful Series B funding round, securing £18 million to propel its innovative surgical robot, the Mona Lisa, into the next phase of development. Spearheaded by healthcare entrepreneur Tony Tan and supported by existing shareholder Zig Ventures, the funding aims to expedite Biobot’s global expansion and enhance its commercial presence. CEO Albert Lee hailed the round’s closure as a significant milestone in Biobot’s mission to revolutionise transperineal biopsy and treatment methodologies.
In a parallel vein, CerraCap Ventures, a prominent player in healthcare innovation investment, has chosen to back Acorai, an innovative company in cardiovascular health technology. This strategic investment is set to catalyse the advancement and deployment of Acorai’s groundbreaking Acorai Heart Monitor (AHM), designed to address critical challenges in heart failure management. AHM’s precision in measuring intracardiac pressures non-invasively marks a transformative leap in heart failure monitoring, empowering healthcare providers with accurate data crucial for effective patient management.
Pixee Medical, renowned for its augmented reality navigation technologies for orthopaedic surgery, has embarked on a significant expansion journey following a €17,5 million capital-raising effort. Led by key investors including Relyens Innovation Santé, UI Investissement, Innovacom, Angelor, and Bpifrance, this transaction positions Pixee Medical to accelerate its growth in the United States and roll out its next generation of innovative products. This infusion of funds underscores Pixee Medical’s commitment to pioneering advancements that optimise surgical outcomes and enhance patient care.
Regulatory Approvals
Just a month ago, Pulse Biosciences, Inc. achieved a major milestone with FDA 510(k) approval for its CellFX nsPFA system, designed for soft tissue ablation in percutaneous and intraoperative surgical procedures. This clearance represents a significant advancement in the realm of non-thermal cellular ablation, empowering clinicians with a precise tool to target cells without affecting adjacent noncellular tissue.
Meanwhile, EDAP TMS garnered FDA breakthrough device designation for its Focal One platform, aimed at treating deep infiltrating endometriosis (DIE). Building upon the FDA’s previous approval of the Focal One HIFU system for prostatic tissue ablation, this designation underscores Focal One’s potential as a non-invasive, robotic ablative solution for addressing endometriosis, a condition affecting millions of women worldwide.
In a similar context, back in February neuro42 received FDA 510(k) clearance for its portable diagnostic MRI scanner, a groundbreaking development poised to transform point-of-care imaging for patients with critical neurological conditions. By eliminating the need for patient transportation to imaging suites, neuro42’s MRI System promises timely diagnosis and improved treatment outcomes, representing a significant leap forward in neurological care delivery.
Clinical Trials
MediView XR unveiled promising results from a trial evaluating its XR90 surgical visualisation and navigation system, showcasing its clinical precision in guiding procedures with unparalleled accuracy. Leveraging 3D X-ray vision, the XR90 system equips physicians with comprehensive insights into a patient’s internal anatomy, empowering them to conduct procedures with heightened precision and efficacy.
Cognito Therapeutics initiated a biomarker substudy within its HOPE pivotal trial, focusing on evaluating the efficacy of its GammaSense Stimulation system in Alzheimer’s disease patients. This substudy, alongside the main trial assessing sensory stimulation therapy, aims to elucidate the therapeutic potential of Cognito’s innovative approach in preserving cognitive function and mitigating disease progression.
Sensome commenced a feasibility clinical study utilising its Clotild® Smart Guidewire in peripheral artery disease (PAD) patients, marking a significant step forward in advancing vascular disease management. Through real-time detection of blood vessel blockages, the Clotild® sensor holds promise in enhancing diagnostic accuracy and optimising treatment strategies for patients with PAD.
Innovation
CMR Surgical launched its Versius system in Sweden, marking a significant milestone as Norra Älvsborgs Sjukhus becomes the first hospital in the Nordics to conduct robotic-assisted surgeries with Versius. This multispecialty robotic surgery programme underscores Versius’s versatility and potential to expand access to minimal access surgery across various medical specialties.
Nanoflex Robotics introduced its remote-ready robotics system for neurovascular procedures in the U.S., offering physicians unprecedented control and precision in complex vascular interventions. By leveraging magnetic, micro-robotic technology, Nanoflex Robotics aims to revolutionise stroke care delivery, minimising treatment delays and maximising patient outcomes.
More recently, Affluent Medical achieved a groundbreaking milestone with the successful first-in-human implant of its minimally invasive urinary incontinence treatment device, Artus. This milestone underscores Affluent Medical’s commitment to addressing unmet clinical needs and improving patient quality of life through innovative medical solutions.
The convergence of technological innovation, regulatory support, and clinical research underscores the MedTech sector’s commitment to driving positive change in healthcare delivery. As we move forward, continued collaboration between industry stakeholders, healthcare providers, and regulatory agencies will be vital in navigating the complexities of bringing new technologies to market while ensuring patient safety and efficacy.
These advancements reflect a concerted effort by companies and investors to push the boundaries of medical technology, with a clear focus on enhancing patient care and outcomes. With such promising developments in the first quarter of 2024, we eagerly anticipate what the rest of the year will bring.
Guided Solutions is the Executive Search partner of choice to the global Medical Device industry. We connect visionary companies with our continually expanding network of 140,000+ medtech professionals, fulfilling the potential of technology and talent.
Whether you have a priority hire, which requires immediate attention, or you are exploring the idea of adding to your team and would like some advice, contact us today and we will guide you through the hiring journey.
